• 00Days
  • 00Hrs
  • 00Mins
  • 00Secs

Program

Preliminary program now available!

The APLAR 2023 official program is scheduled in the Chiang Mai time zone (GMT+7). To check the program times in your location, use our time zone converter

As more information becomes available – this page will be updated so please make sure to check back regularly. 

0800
REGISTRATION
0830-0900
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 1
Workshop begins at 0830.

View information here
0900-1200
MRI Axial Imaging Course
Course begins at 0900.

View information here
1200-1245
BREAK
1245-1445
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 1
Continued
MRI Axial Imaging Course
Continued
1445-1515
BREAK
1515-1700
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 1
Continued - Workshop finishes at 1700 for this day.
MRI Axial Imaging Course
Course finishes at 1600.
0800-0830
REGISTRATION
0830-0900
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 2
Continued - Workshop begins at 0830.

View information here
0900-1000
GRAPPA Symposium
Symposium begins at 0900.

View information here
mRSS Assessment Course
Course begins at 0900.

View Information here
1000 -1030
BREAK
1030 -1200
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 2
Continued
GRAPPA Symposium
Symposium finishes at 1200.
mRSS Assessment Course
Course finishes at 1200.
1200 -1245
BREAK
1245 -1400
1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level | Day 2
Continued - Workshop continues until 1700.
Changing and perspective of academic journals
Course begins at 1245, and finishes at 1400.

View information here
1700-1800
Opening Ceremony
Included in registration. View more information here
1800-1930
Welcome Reception and Official Opening of Exhibition Hall
Included in registration. View more information here
ROOM
Capacity
B7
150 theatre capacity
B2
50 classroom capacity
B8
150 classroom capacity
B9
250 theatre capacity
--
Info coming soon
B3
100 classroom capacity
B4
100 classroom capacity
B5
100 classroom capacity
A2
30 u-shape
0830-0900
REGISTRATION
0900-1000
Cont.
MSUS Workshop
Day 2
Cont.
MRI Imaging Course
Day 2
GRAPPA Symposium
Allied Health Course
APLAR Industry workshop 1

set up
APLAR Industry workshop 2

set up
APLAR Industry workshop 3

set up
APLAR Executive Committee Meeting
1000 -1030
COFFEE BREAK
COFFEE BREAK
1030 -1200
Cont.
MSUS Workshop
Day 2
Cont.
MRI Imaging Course
Day 2
Cont.
GRAPPA Symposium
Cont.
Allied Health Course
APLAR Meetings
1200 -1245
LUNCH BREAK
LUNCH BREAK
1245 -1400
Cont.
MSUS Workshop
Day 2
Cont.
MRI Imaging Course
Day 2
Cont.
GRAPPA Symposium
Cont.
Allied Health Course
APLAR Meetings
1400-1700
AFTERNOON TEA
Industry pre-congress workshop 1
Industry pre-congress workshop 2
Industry pre-congress workshop 3
APLAR Meetings
ROOM
Capacity
PLENARY/CONCURRENT 1 - Exhibition Hall 1
2,000 capacity
1700-1800
Opening Ceremony
ROOM
Capacity
Exhibition Hall 3 - exhibition
1800-1930
Welcome Reception and Official Opening of Exhibition Hall
0800-0930
Plenary session 1

Chairpersons: Catherine Hill and Masayoshi Harigai

Update treatment in Behcet's disease
Wafa Madanat

TBA
Xinping Tian

Geo-ethnic variations in vasculitis disease
Debashish Danda
0930-1030
Plenary session 2

Chairpersons: Ho So

What do we mean about the nature of scleroderma disease from the EU-US and Asia-Pacific database?
Andrea Low

Update of guidelines on treatments of interstitial lung disease in connective tissue diseases from ERS/EULAR
Oliver Distler
1030-1055
BREAK AND POSTER VIEWING
1055-1200
Morning symposium 1
Morning symposium 2
Morning symposium 3
1200-1315
SpA / PsA session

Chairpersons: Nazrul Islam and Muhammad Ahmed Saeed

Juvenile SpA: pathogenisis, assessment and outcome
Amita Aggarwal

Gut dysbiosis in axial spondyloarthritis
Hong Ki Min

Q&A
Large vessel vasculitis 2023 update
Coordinated by the APLAR Vasculitis SIG

Chairpersons: Debashish Danda

Epidemiology and clinical features of GCA
Catherine Hill

Management of GCA
Frank Butthereit

Takayasu arteritis and reproduction
Takako Miyamae

Panel discussion
Catherine Hill, Frank Butthereit, Takako Miyamae and Masayoshi Harigai

Closing remarks
Debashish Danda
Scleroderma session
Coordinated by the APLAR Scleroderma SIG

Chairpersons: Andrea Low and Jasmin Raja

Novel therapies in SSc and lessons learnt from clinical trials
Oliver Distler

Bridging the valley of death from bench to bedside in systemic sclerosis
Tohru Takeuchi

Q&A

A challenging therapeutic case of SSc panel discussion
ChingChing Foocharoen, Oliver Distler and Tohru Takeuchi
Insight antiphospholipid syndrome and associated diseases

Chairpersons: Sami Salmon and Kenji Oku

Update in pathogenesis and relevance antibodies
Takao Koike

Controversy of APS in SLE
Laniyati Hamijoyo

Clinical features and treatments in interferon-driven APS-SLE
Yoshiya Tanaka
1315-1435
Lunch symposium 1
Lunch symposium 1
BREAK AND POSTER VIEWING
1435-1550
Axial manifestation of psoriatic arthritis

Chairpersons: Sang-Heon Lee and Praveena Chiowchanwisawakit

Clinical features of axial manifestation of psoriatic arthritis
Ved Chaturvedi

TBA
Katy Leung

Treatment of axial PsA
Lai-Shan Tam
Myositis session
Coordinated by the APLAR myositis SIG

Chairpersons: Iris Tang and Takahisa Gono

Myositis related ILD: from bench to bedside
Takuya Kotani

Improving IIM classification criteria: where are we now?
Jessica Day

Q&A
Paedatric rheumatology workforce: fill the gap session
Coordinated by the APLAR Paediatric SIG

Innovations in training
Sirirat Charuvanij

COE: blueprint for lesser mortals
Surjit Singh

Q&A
Genetics session
Coordinated by the APLAR Genetics SIG

Chairpersons: Michael Tee and Chikashi Terao

Genetic approach to identify new targeted therapies in SLE
Prapaporn Pisitkun

Personalised medicine in rheumatology: leveraging genetic insights to disease predict
Yi-Ming Chen

Genetic polymorphism in rheumatoid arthritis
Suleman Khan

Q&A
1550-1615
BREAK AND POSTER VIEWING
1615-1730
EULAR session: Early diagnosis and management of arthritis

Chairpersons: Yoshiya Tanaka

A journey through recent EULAR management recommendations
Anna-Maria Iagnocco

Early RA diagnosis - where are we now?
Daniel Aletaha

Modern imaging tools for early SpA diagnosis
Xenofon Baraliakos

Q&A
AYR session
Coordinated by the AYR SIG

Chairpersons: Priscilla Wong and Himantha Atukorale

Immunodeficiencies presenting to the rheumatology clinic
Justina Tan

A novel approach to anti-cytokine sydnromes - when autoimmunity presents as infections out of the blue
Xin Li

Q&A
Rheumatology potpourri 1

Chairpersons: Steven Sawyers and Nuntana Kasitanon

Biomarker and immunology aspect in fibromyalgia
Geoffrey Littlejohn

Metabolomic in rheumatic diseases
Ramnath Misra

Sleep disorders in rheumatic diseases
Zhifeng Gu
Women's Health & Reproductive Issues in RMDs
Coordinated by the Reproductive SIG

Chairpersons: Rohini Handa

Introduction into pregnancy and rheumatic disease with focus on SLE and APLS
Samar Al-Emadi

Inflammatory arthritis including RA, SpA (efect of the disease on pregnancy and fetal comes)
Mu Rong

Q&A
1800-1900
Evening symposium 1
Evening symposium 2
Evening symposium 3
ROOM
Capacity
Exhibition Hall 1
2,000 capacity
Convention Hall 1
1,700 capacity
Leelawadee Hall 1
400 theatre capacity
Leelawadee Hall 2
400 theatre capacity
B1
100 theatre capacity
Exhibition Hall 3
0800-0900
0900-1030
1030-1055
BREAK AND POSTER VIEWING
1055-1200

Morning symposium 1
Sponsored by AbbVie

Morning symposium 2

Morning symposium 3

Morning symposium 4
1200-1315
Concurrent session
SIG Rheumatoid arthritis
Concurrent session
SIG Vasculitis
Concurrent session
COVID-19 infection and rheumatic diseases
Concurrent session
Personalized treatment in idiopathic inflammatory myopathy (IIM)
Concurrent session
SIG Sjogren
1315-1435

Lunch symposium 1
Sponsored by Pfizer

Lunch symposium 2
1320-1350
Meet the experts 1
Sponsored by GSK
1400-1430
Meet the experts 2
Sponsored by Boehringer Ingelheim
1435-1550
Concurrent session
1. Update treatment in osteoporosis
Sequential and combination of osteoporosis therapy
Denosumab discontinuation

2.Osteoporosis treatment and cardiovascular effects
Relationship of bone and cardiovascular system
Cardiovascular effects of osteoporosis therapies
Concurrent session
SIG Myositis
Update on idiopathic inflammatory myopathy diagnosis

From pathology to diagnosis
Myositis specific antibodies in IIM and clinical relevance
Concurrent session
SIG Pediatric
Children with rheumatic diseases during COVID-19 era

Immunogenicity and effectiveness of COVID-19 vaccination
Outcomes of autoimmune diseases after COVID-19 infection/vaccination
Concurrent session
IgG4 related disease
Updated mechanisms Perspective treatment Myositis specific antibodies in IIM and clinical relevance
0800-0900
Advanced therapy in rheumatic diseases

Chairpersons: Lai-Shan Tam and Andrea Low

Treatment of non-radiographic axial spondyloarthritis: which kinds of medicine should be the most appropriate treatment for non-radiographic axial spondyloarthritis and when to start?
Mitsumasa Kishimoto
Abstract session
Abstract session
0900-1030
Plenary session 3

Chairpersons: Rohini Handa and Yi-Hsing Chen

Rational DMARDs use in Asian context
Tsutomu Takeuchi

How to taper and/or discontinue DMARDs (csDMARDs, biologics and JAKi) in RA patients with sustained remission
Daniel Aletaha

Non-selective vs selective JAK inhibitors for RA: effectiveness and safety
Peter Nash
1030-1100
BREAK AND POSTER VIEWING
1100-1200
Personalized treatment in idiopathic inflammatory myopathy (IIM)

Chairpersons: Latika Gupta and Jasmin Raja

IIM associated ILD
Hideaki Tsuji

Malignancy screening and treatment for IIM associated cancer
Guochun Wang
IgG4 related disease

Chairpersons: Atsushi Kawakami and Prapaporn Pisitkun
Rheumatology Potpourri 2

Chairpersons: Yi-Hsing Chen and Nuntana Kasitanon

Renal and neurological problems in Sjogren's syndrome
Sandhya Pulukool

Imaging in large vessel vasculitis
Naoto Tamura
1200-1315
Osteoarthritis session
Coordinated with the APLAR Osteoarthritis SIG

Chairpersons: Keith Lim

Joint effusions and knee OA
Keith Lim

TBA
Changhai Ding

Predictors of response
Benny Antony

Q&A
Recent advances in psoriatic arthritis
Coordinated by the APLAR SpA SIG

Chairpersons: Nizar Abdulateef Jassim and Kichul Shin

State of the art therapeutics for PsA
Lai-Shan Tam

Precision medicine in predicting treatment response in psoriatic arthritis
Ippei Miyagawa

Role of MRI in PsA
Ashish Mathew

Q&A
Social commitment and patient outreach session
Coordinated by the Social commitment and patient outreach SIG

Chairpersons: Syed Atiqul Haq and Nighat Ahmad

Introduction
Syed Atiqul Haq and Nighat Ahmad

Educating patients: show should a rheumatology proceed
A T M Tanveer Hasan

The HomeRheum Status: Current state of rheumatology workforce in Asia-Pacific
Jonathan Paul Consignado

Q&A

Closing remarks
Syed Atiqul Haq and Nighat Ahmad
1315-1415
BREAK AND POSTER VIEWING
1415-1530
Best management of SLE
Coordinated by the SLE SIG

Chairpersons: CC Mok and Yoshiya Tanaka

Impact of ethnic and social inequity on outcome of SLE
Sarfaraz Hasni

Assessment of disease activity of SLE
Kathryn Connelly

COVID-19 in SLE
Syahrul Sazliyana

Successful pregnancy and gender equity in SLE
Sandra Navarra

Q&A
Rheumatoid arthritis session
Coordinated by the RA SIG

Chairpersons: Kunihiro Yamaoaka

Recommendation update
Kunihiro Yamaoka

Improvement of early diagnosis and management of rheumatoid arthritis using digital health system
Chun Li

Q&A
Emerging treatment strategies for osteoporosis
Coordinated by the Osteoporosis SIG

Chairpersons: Lau Tang Ching and Sumapa Chaiamnuay

What is hot and what is not in bone?
Kenneth Saag

Debate - treat or target for osteoporosis, myth or reality?
Lau Tang Ching and Sumapa Chaimnuay

Q&A
1530-1600
BREAK AND POSTER VIEWING
1600-1715
Digital health and clinical decision support system in rheumatology Best management of SLE
Coordinated by the Digital Health and Telemedicine SIG

Chairpersons: Yew Kuang Cheng

Why should we use artificial intelligence in rheumatic disease?
Sakir Ahmed

Artificial intelligence implication in rheumatic diseases
Lisa Traboco
Current evidence of osteoarthritis management

Chairpersons: Nazrul Islam and Keith Lim

Update pathogenesis of osteoarthritis
Inoshi Atukorala

Update treatment in osteoarthritis
Syed Atiqul Haq

What's new in hand osteoarthritis?
Benny Anthony
Crystal induced arthritis session
Coordinated by the Crystal induced arthritis SIG

Chairpersons: Helen Keen and Jose Paulo Lorenzo

The intersection of gout and chronic kidney disease
Evelyn Salido

Gaos in the current knowledge of evalutation and treatment of gout
Binit Vaidya

CPPD the ignored disease
Sami Salmon

APLAR gout registry updates and preliminary results
Kanon Jatuworapruk

Q&A
1715-1830
Pain in rheumatic musculoskeletal disorders: A COPCORD perspective
Coordinated by the Epidemiology COPCORD SIG

Chairpersons: Arvind Chopra and Samar Al-Emadi

What a pain it is!
Arvind Chopra

Pain beyond inflammation in rheumatic disorders
Shin-Seok Lee

Lessons on capturing pain from COPCORD studies
Leonila Dans

Epidemiology of fibromyalgia in rheumatic diseases
Soosan Soroosh
br> Sex differences in perception of pain in the COPCORD domain
Binit Vaidya

Future COPCORD research agenda for pain in rheumatic diseases
Ashish Mathew

Q&A
Gout in women

Chairpersons: Jose Paulo Lorenzo and Worawit Louthrenoo

Urate biology
Helen Keen

Clinical presentations and management
Monika De Silva

Patient preferences in gout management
Jisoo Lee
Chronic pain session
Coordinated by the Chronic pain SIG
1930-2130
Joint Presidential & Gala Dinner
Not included in registration. Tickets available at additional cost. View more information and registration information here
0800-0900
Relapse of adult-onset Still disease

Chairpersons: Wafa Wadanat and Samar Al-Emadi

Genetics and risk factors
Alireza Khabbazi

How to treat and efficacy of tight control
Dae Hyun Yoo
Gout session

Chairpersons: Helen Keen and Ronald Yip

Emerging strategies for treating difficult gout
Worawit Louthrenoo
Abstract session
0900-1030
Plenary session 4

Chairpersons: Laniyati Hamijoyo and Sandra Navarra

Future direction of optimal treatment in SLE
Eric Morand

TBA
Nan Shen

New concepts of lupus nephritis treatment
CC Mok
1030-1050
BREAK AND POSTER VIEWING
1050-1205
Imaging SIG session

Chairpersons: Kong Kok Ooi and Phonpen Akarawatcharangura Goo

Ultrasonography in large vessel vasculitis (US LVV) - an update
Helen Keen

Ultrasonography in Systemic Lupus Erythematosus
Farzana Shumy

Q&A
Hot topics in rheumatoid arthritis

Chairpersons: Manathip Osiri and Cho Mar Lwin

Advances in biological targets in RA
Kazuhiko Yamamoto

Should csDMARDs be maintained lifelong after sustained remission?
Mu Rong
Highlights in Paediatric Rheumatology

Chairpersons: Sumaira Farman

Cytokine storms: similarities and dissimilarities between MAS and MIS-C
Soamarat Vilaiyuk

COVID-19 vaccination in pediatric rheumatic diseases: whre are we going forward?
Thaschawee Arkachaisri

Autoinflammatory diseases in Asian Pacific: are we different?
Sulaiman Al-Mayouf
1205-1305
BREAK AND POSTER VIEWING
1305-1420
Reproductive aspects in rheumatic disease

Chairpersons: Adeeba Al-Herz

Reproductive health in inflammatory arthritis
Samar Al-Emadi

Reproductive health and biologics
Latika Gupta

Pregnancy outcomes in SLE
Sandra Navarra
ACR session
Updating Imaging in rheumatology

Chairpersons: Katy Leung and Gavin Lee

Imaging modalities for CNS vasculitis evaluation
Naoto Tamura

Imaging update in spondyloarthritis
Ashish Jacob Mathew

Imaging update in osteoarthritis
Hyun Ah Kim
1420-1440
BREAK AND POSTER VIEWING
1440-1555
COVID-19 and beyond

Chairpersons: Sandhya Pulukool and Kichul Shin

Autoimmunity after COVID infection
Prapaporn Pisitkun

Comparative outcome of patients with rheumatic disease affected by COVID-19 infection
Kuo-Tung Tang

COVID epidemiology and its relationship with rheumatic diseases
Catherine Hill
Recent understanding and perspective of Sjogren's syndrome
Coordinated by the APLAR Sjogren SIG

Chairpersons: Sapan Padya

GWAS in Sjogren
Maureen Rischmueller

Recent understanding and perspective of Sjogren's syndrome
Atsushi Kawakami

Q&A
What's new in osteoporosis?

Chairpersons: Sumapa Chaiamnuay and Lau Tang Ching

Epidemiology of bone health in patients with rheumatic diseases
Arvind Chopra

New evidence of bone safety of glucocorticoids in the treatment of inflammatory rheumatic disease
Kenneth Saag

Long-term management strategies for osteoporosis: continuous or intermittent?
Mustafa Khalid Al Izzi
1555-1625
Closing Ceremony
Translate »